Physician profile
Jay R Long
NPI 1447364963
$612.13
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $73.87 · 2021: $11.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $146.76 | 2019-2020 | |
| Covidien LP | $130.09 | 2019 | |
| Novo Nordisk INC | $101.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.07 | 2019-2020 | |
| Pfizer INC. | $37.69 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $25.20 | 2019 | |
| Abbvie INC. | $23.44 | 2019 | |
| Allergan, INC. | $17.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.72 | 2019 | |
| Lilly USA, LLC | $13.42 | 2019 | |
| Glaxosmithkline, LLC. | $11.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.